Characterizing the epidemiology of Mycoplasma pneumoniae infections in China in 2022-2024: a nationwide cross-sectional study of over 1.6 million cases
- PMID: 40146610
- PMCID: PMC11980206
- DOI: 10.1080/22221751.2025.2482703
Characterizing the epidemiology of Mycoplasma pneumoniae infections in China in 2022-2024: a nationwide cross-sectional study of over 1.6 million cases
Abstract
Mycoplasma pneumoniae (MP) is a leading cause of community-acquired pneumonia (CAP), accounting for 10-40% of cases in children. In China, the high prevalence of macrolide-resistant MP (MRMP) and recurrent MP epidemics place a significant burden on the healthcare system. Leveraging data from over 1.6 million cases, this study provides a comprehensive analysis of the epidemiological characteristics of MP across China. Seasonal patterns analysis revealed three distinct transmission zones in China. Transmission Zone 1 exhibited two annual epidemic peaks, while Zones 2 and 3 showed a single annual peak of distinct timings. Notably, winter travel to popular tourist destinations appears to influence MP infection patterns in China. Age- and sex- specific analysis indicated male newborns aged [0-1) years face a 1.67 times higher risk of MP infection compared to females. Conversely, females aged [23-38) years have a higher infection risk, likely due to their caregiving roles. The proportion of MRMP surged from 80.00% to 93.02% between July 2023 and May 2024, with a median growth rate of 10.21%. This rapid increase contrasts sharply with the modest 5.3% rise observed from 2011 to 2019, and we attribute this escalation in part to the growing prevalence of the T1-3R clade strain in China. These findings have important implications for the identification of high-risk population, place, and time for more targeted efforts of prevention and treatment. Furthermore, the rapidly increased proportion of MRMP in the 2023-2024 season raises a concerning signal regarding antibiotic use.
Keywords: China; Mycoplasma pneumoniae; age- and sex- specific; macrolide-resistant; transmission zones.
Conflict of interest statement
No potential conflict of interest was reported by the author(s).
Figures



Similar articles
-
Molecular characteristics of macrolide-resistant Mycoplasma pneumoniae in children with community-acquired pneumonia in Urumqi, Xinjiang, China in autumn, winter, and spring 2023-2024.J Infect Public Health. 2025 Jun;18(6):102748. doi: 10.1016/j.jiph.2025.102748. Epub 2025 Mar 12. J Infect Public Health. 2025. PMID: 40107151
-
[Epidemiological characteristics of co-infection with drug-resistant Mycoplasma pneumoniae and non-bacterial pathogens in a children's hospital in Ningbo City from 2021 to 2024].Zhonghua Yu Fang Yi Xue Za Zhi. 2025 Mar 6;59(3):336-343. doi: 10.3760/cma.j.cn112150-20240911-00731. Zhonghua Yu Fang Yi Xue Za Zhi. 2025. PMID: 40107784 Chinese.
-
Epidemiological changes of Mycoplasma pneumoniae among children before, during, and post the COVID-19 pandemic in Henan, China, from 2017 to 2024.Microbiol Spectr. 2025 Jul;13(7):e0312124. doi: 10.1128/spectrum.03121-24. Epub 2025 Jun 9. Microbiol Spectr. 2025. PMID: 40488359 Free PMC article.
-
Expert consensus on the diagnosis and treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children.World J Pediatr. 2024 Sep;20(9):901-914. doi: 10.1007/s12519-024-00831-0. Epub 2024 Aug 14. World J Pediatr. 2024. PMID: 39143259 Free PMC article. Review.
-
Disease burden and macrolide resistance of Mycoplasma pneumoniae infection in adults in the Asia-Pacific region.Int J Antimicrob Agents. 2024 Aug;64(2):107205. doi: 10.1016/j.ijantimicag.2024.107205. Epub 2024 May 14. Int J Antimicrob Agents. 2024. PMID: 38754527 Review.
References
-
- GBD 2021 Lower Respiratory Infections and Antimicrobial Resistance Collaborators . Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990–2021: a systematic analysis from the global burden of disease study 2021. Lancet Infect Dis. 2024;24(9): 974–1002. doi:10.1016/S1473-3099(24)00176-2 - DOI - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous